By Cristina Roca 
 

Sanofi SA (SAN.FR) and Regeneron Pharmaceuticals Inc. (REGN) said Tuesday that Dupixent has been approved for the treatment of severe asthma in the European Union.

The two pharmaceutical companies developed the drug jointly, they said in a press release.

Dupixent is approved in the EU to treat moderate-to-severe atopic dermatitis in adults, and has now been given approval by the European Commission to treat severe asthma with type 2 inflammation in adults and patients 12 years and older.

 

Write to Cristina Roca at cristina.roca@dowjones.com; @_cristinaroca

 

(END) Dow Jones Newswires

May 07, 2019 09:24 ET (13:24 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Sanofi (NASDAQ:SNY)
Historical Stock Chart
From Aug 2020 to Sep 2020 Click Here for more Sanofi Charts.
Sanofi (NASDAQ:SNY)
Historical Stock Chart
From Sep 2019 to Sep 2020 Click Here for more Sanofi Charts.